公开(公告)号：US20240368250A1

公开(公告)日：2024-11-07

申请号：US18443751

申请日：2024-02-16

Applicant: Ablynx N.V. ,  Sanofi

Inventor： Tom Van Bogaert ,  Judith Verhelst ,  Carlo Boutton ,  Wilbert De Witte

IPC: C07K14/765

Abstract: The present technology relates to polypeptides binding to the neonatal Fc receptor. More particularly, the present technology provides polypeptides binding to the neonatal Fc receptor and comprising (i) at least one domain comprising a serum albumin protein and/or at least one domain specifically binding to a serum albumin protein and (ii) an Fc domain of an immunoglobulin G (IgG).

公开(公告)号：US12006352B2

公开(公告)日：2024-06-11

申请号：US16823412

申请日：2020-03-19

Applicant: Ablynx N.V. ,  Sanofi

Inventor： Judith Baumeister ,  Marie-Paule Lucienne Armanda Bouche ,  Carlo Boutton ,  Marie-Ange Buyse ,  Veerle Snoeck ,  Stephanie Staelens ,  Bruno Dombrecht ,  Peter Schotte ,  Cedric Jozef Neotere Ververken ,  Gerald Beste ,  Guy Hermans ,  Soren Steffensen ,  Alexander Szyroki ,  Tinneke Denayer

IPC: C07K16/00 ,  C07K16/18 ,  A61K39/00 ,  A61K39/395 ,  C07K16/28 ,  C07K16/42 ,  G01N33/53 ,  G01N33/543 ,  G01N33/68

CPC classification number: C07K16/00 ,  C07K16/18 ,  A61K39/39533 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2875 ,  C07K16/42 ,  C07K16/4283 ,  C07K2317/22 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/35 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/30 ,  G01N33/5306 ,  G01N33/54393 ,  G01N33/6854 ,  G01N33/6857

Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay). Such predictive assays could for example be used to test whether a given ISV could have a tendency to give rise to such protein interference and/or such a signal; to select ISV's that are not or less prone to such protein interference or to giving such a signal; as an assay or test that can be used to test whether certain modification(s) to an ISV will (fully or partially) reduce its tendency to give rise to such interference or such a signal; and/or as an assay or test that can be used to guide modification or improvement of an ISV so as to reduce its tendency to give rise to such protein interference or signal;—methods for modifying and/or improving ISV's to as to remove or reduce their tendency to give rise to such protein interference or such a signal;—modifications that can be introduced into an ISV that remove or reduce its tendency to give rise to such protein interference or such a signal; ISV's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved ISV's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal.

公开(公告)号：US11708404B2

公开(公告)日：2023-07-25

申请号：US17719496

申请日：2022-04-13

Applicant: Ablynx N.V. ,  Sanofi

Inventor： Marie-Ange Buyse ,  Carlo Boutton

IPC: C07K16/18 ,  C07K16/00 ,  C07K16/28 ,  C07K16/42 ,  C07K16/32 ,  C07K16/30 ,  C07K16/24

CPC classification number: C07K16/18 ,  C07K16/00 ,  C07K16/24 ,  C07K16/241 ,  C07K16/244 ,  C07K16/28 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2875 ,  C07K16/30 ,  C07K16/32 ,  C07K16/42 ,  C07K16/4291 ,  C07K2317/22 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/31

Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).

公开(公告)号：US20220332807A1

公开(公告)日：2022-10-20

申请号：US17704063

申请日：2022-03-25

Applicant: Ablynx N.V. ,  Sanofi

Inventor： Marie-Ange Buyse ,  Carlo Boutton

IPC: C07K16/18 ,  C07K16/00 ,  C07K16/28 ,  C07K16/42 ,  C07K16/32 ,  C07K16/30 ,  C07K16/24

Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).

公开(公告)号：US20220213215A1

公开(公告)日：2022-07-07

申请号：US17553908

申请日：2021-12-17

Applicant: Ablynx N.V. ,  Sanofi

Inventor： Daniel Janssen ,  Carlo Boutton ,  Evelyne Dombrecht ,  Bram Laukens ,  Paolo Meoni ,  Lily Pao ,  Jan Pype ,  Peter Schotte ,  Benedikte Serruys ,  Ana Paula Vintem ,  Diane Van Hoorick

IPC: C07K16/30 ,  C07K16/28 ,  A61P35/00

Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from cancer. Specifically, the technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that one ISVD binds to TCR and at least two ISVDs bind to GPC3. The present technology also provides nucleic acids, vectors and compositions.

公开(公告)号：US11485777B2

公开(公告)日：2022-11-01

申请号：US17215121

申请日：2021-03-29

Applicant: Ablynx N.V. ,  Sanofi

Inventor： Marie-Ange Buyse ,  Carlo Boutton

IPC: C07K16/18 ,  C07K16/00 ,  C07K16/28 ,  C07K16/42 ,  C07K16/32 ,  C07K16/30 ,  C07K16/24

Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).

公开(公告)号：US12180268B2

公开(公告)日：2024-12-31

申请号：US15311564

申请日：2015-05-13

Applicant: Ablynx N.V. ,  Sanofi

Inventor： Marie-Ange Buyse ,  Carlo Boutton

IPC: C07K16/18 ,  C07K16/00 ,  C07K16/24 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C07K16/42

Abstract: VH domain, in which: (i) the amino acid residue at position 1 12 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 1 10 is one of K or Q; and (iv) in each of cases (i) to (hi), the amino acid at position 1 1 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).

公开(公告)号：US20240132624A1

公开(公告)日：2024-04-25

申请号：US18360393

申请日：2023-07-27

Applicant: Ablynx N.V. ,  Sanofi

Inventor： Tom Van Bogaert ,  Judith Verhelst ,  Stephanie Staelens ,  Carlo Boutton ,  Wilbert De Witte ,  Thomas Bertrand

IPC: C07K16/42 ,  A61K47/68 ,  C07K16/18

CPC classification number: C07K16/42 ,  A61K47/6873 ,  C07K16/18 ,  C07K2317/31 ,  C07K2317/569

Abstract: The present invention relates to polypeptides that are capable of binding to a specific epitope on the neonatal Fc receptor (FcRn). In particular, the present invention relates to novel and improved polypeptides comprising immunoglobulin single variable domains (ISVDs), such as heavy-chain single variable domains, that are capable of binding to a specific epitope on FcRn. The invention further relates to constructs, compounds, molecules or chemical entities that comprise at least one of these ISVDs binding to a specific epitope on FcRn. The present invention further relates to methods for producing such polypeptides as well as to uses of such polypeptides for diverse applications, including but not limited to the extension of the half-life in vivo of therapeutic compounds and/or the prevention and/or treatment of a disease and/or disorder, such as but not limited to a proliferative disease, an inflammatory disease, an infectious disease or an autoimmune disease.

公开(公告)号：US20220332806A1

公开(公告)日：2022-10-20

申请号：US17697508

申请日：2022-03-17

Applicant: Ablynx N.V. ,  Sanofi

Inventor： Marie-Ange Buyse ,  Carlo Boutton

IPC: C07K16/18 ,  C07K16/00 ,  C07K16/28 ,  C07K16/42 ,  C07K16/32 ,  C07K16/30 ,  C07K16/24

Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).

公开(公告)号：US20240343823A1

公开(公告)日：2024-10-17

申请号：US18432750

申请日：2024-02-05

Applicant: Ablynx N.V. ,  Sanofi

Inventor： Daniel Janssen ,  Carlo Boutton ,  Evelyne Dombrecht ,  Bram Laukens ,  Paolo Meoni ,  Lily Pao ,  Jan Pype ,  Peter Schotte ,  Benedikte Serruys ,  Ana Paula Vintem ,  Diane Van Hoorick

IPC: C07K16/30 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28

CPC classification number: C07K16/303 ,  A61P35/00 ,  C07K16/2809 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/30

Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from cancer. Specifically, the technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that one ISVD binds to TCR and at least two ISVDs bind to GPC3. The present technology also provides nucleic acids, vectors and compositions.